AusHealth’s collaboration with Epidermolysis Bullosa (EB) Research Partnership Australia is advancing the use of phage therapy to treat children with life-threatening genetic disorders.

Epidermolysis Bullosa is the umbrella term for a group of rare genetic disorders that attack the body’s largest organ – the skin.
This painful disorder causes layers of skin (including layers around internal organs) to tear, blister and shear off, leading to severe pain, disfigurement and wounds that may never heal.

Dr Tina Lavranos manages a multi-million-dollar portfolio of research projects being funded by medical research charity, AusHealth. Tina knows how hard it is to pitch for money -- in the 1990s, she was a young post-doc seeking funding from the federal government. Now she’s on the other side of the table, and it's her job to know the difference between 'pitch perfect' and 'pitch poor'.

Here are her six golden rules to consider before trying to persuade a funding body to part with their cash...

On the latest Hamish & Andy podcast (23 April), Andy Lee revealed how he'd discovered a flask of suspicious powder behind the wall of his 1876 house in Melbourne.

He and colleague Hamish Blake wanted to know whether it was some kind of 19th-Century poison - or another illicit substance? They put the call out for a qualified person to provide answers and AusHealth's expert toxicologist Dr John Edwards stepped up.

Solutions for Manufacturing Advanced Regenerative Therapies (SMART) CRC has been announced today by The Hon Ed Husic MP Minister for Industry and Science.

AusHealth is one of the architects of the new cooperative research centre, designed to grow Australia’s biomanufacturing industry and take radical regenerative therapies out of the laboratory and into the real world.

Antimicrobial resistance is predicted to cause 10 million deaths by 2050. Could phage therapy be the solution?

This week saw the official launch of the AusHealth Phage Therapy Centre. It’s home to a team of researchers who are taking up arms against one of the greatest challenges modern medicine faces – the rise of antimicrobial resistance.

The Platypep venom project, funded by AusHealth since 2016, has taken another step toward creating an Australian-made version of Ozempic.

The research team has successfully identified a ‘hero peptide’ – derived from platypus venom – that reduces food intake, prevents weight gain and improves metabolic health in mice.